Exact Science Co., Ltd.
Exact Science Co., Ltd. launches “Breast Cancer Treatment.jp” website for breast cancer patients
……
Exact Science Co., Ltd. (Headquarters: Chiyoda-ku, Tokyo,
Representative Director: Kazuhiro Matsumura) will launch Breast Cancer Treatment.jp (http://nyuganchiryo.jp
[Image 1
Website for breast cancer patients “Breast Cancer Treatment.jp” top page In addition to providing information on breast cancer types and treatments, this site provides information on tests that help determine post-operative treatment, and “shared decision-making” where doctors and patients decide on a treatment plan through consultation. We will introduce information that will be helpful when choosing a treatment policy. We will also post patient interview videos and introduce stories of patients choosing treatment methods through communication with their doctors.
In recent years, breast cancer treatment has made significant progress, and it has become possible to select more effective treatments for each patient. Through this site, we will provide general information to breast cancer patients.
[Overview of “Breast Cancer Treatment.jp” website for breast cancer patients] ●Site name Breast cancer treatment.jp
●Release date: Sunday, December 3, 2023
●Main Contents What are the types of breast cancer/What types of treatments are there for breast cancer? /What is a multigene assay that helps predict the risk of postoperative recurrence and determine the need for anticancer drugs? /Shared decision making/Video page ●URL/QR code http://nyuganchiryo.jp
[Image 2
About Exact Science Corporation, a group company of Exact Science Corporation Exact Science Corporation is a company headquartered in Madison, Wisconsin, USA, whose mission is to open up new possibilities for cancer treatment through cutting-edge technology based on the genome (patient’s genetic information). We are one of the world’s leading healthcare companies that provides cancer screening tests and genomic diagnostic tests.
We provide you with the information you need to take early,
life-changing actions. Building on the success of our colon cancer screening and Oncotype tests, we are investing in our pipeline to develop innovative solutions for use before, during and after cancer diagnosis.
Exact Science Co., Ltd. is a group company of Exact Science Corporation. For more information, please visit https://www.exactsciences.com/, https://www.exactsciences.com/jp.
You can also find us on Twitter @ExactSciences and on Facebook Exact Sciences. “Forward-looking statements”
This news release contains statements regarding Exact Science Corporation’s expectations, expectations, intentions, beliefs and strategies regarding the future. These forward-looking statements are based on assumptions made by Exact Science Corporation as of the date of this news release and are subject to known and unknown risks that may cause actual results, conditions or events to differ materially from expectations. and contains uncertainty. Therefore, you should not place undue reliance on forward-looking statements. Risks and uncertainties that may affect Exact Science Corporation’s
forward-looking statements are discussed in Exact Science
Corporation’s most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-K. Q) in the “Risk Factors” section and in other reports filed with the Securities and Exchange Commission. Exact Science Corporation undertakes no obligation to publicly update any forward-looking statements, whether written or oral, whether as a result of new information, future developments or otherwise.